How Does Ovranette Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Ovranette Works
- Active Ingredients: Levonorgestrel (150 mcg, progestogen) and ethinylestradiol (30 mcg, estrogen).
- Primary Actions: Prevents ovulation, thickens cervical mucus (sperm barrier), and alters the endometrium to inhibit implantation.
- Onset & Duration: Contraceptive protection starts immediately if taken on day 1 of cycle; otherwise takes 7 days. Each tablet maintains effects for 24 h.
- Metabolism: Both hormones are metabolised in the liver (mainly CYP3A4) and excreted in urine and faeces as inactive conjugates.
- Non‑contraceptive benefits: Reduces menstrual pain, heavy bleeding, and long‑term risk of ovarian/endometrial cancer.
Ovranette is a combined oral contraceptive pill that uses two hormones to prevent pregnancy by targeting the hypothalamic‑pituitary‑ovarian axis and creating multiple barriers to fertilisation. Below we explain the science behind each component.
Important Medical Advice
Do not take Ovranette if you are pregnant, breastfeeding, or have a history of blood clots, certain cancers, or severe liver disease. Seek immediate medical help if you experience painful leg swelling, sudden chest pain, difficulty breathing, severe headache, or visual disturbances — these can be signs of a blood clot or stroke.
Chemical Composition & Molecular Structure
Ovranette 150/30 coated tablets contain two active substances: levonorgestrel (a second‑generation progestogen) and ethinylestradiol (a synthetic estrogen). Each tablet also contains excipients including lactose monohydrate, maize starch, povidone, magnesium stearate, talc, sucrose, and coating agents (polyethylene glycol 6000, calcium carbonate, white wax, carnauba wax).
Structural Details
(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one
A potent progestogen derived from 19‑nortestosterone. It has high affinity for progesterone receptors and some androgenic activity. Its structure includes an ethinyl group at C17, which slows metabolism.
19‑nor‑17α‑pregna‑1,3,5(10)‑trien‑20‑yne‑3,17‑diol
A synthetic oestrogen with an ethinyl group at C17 that delays hepatic breakdown, allowing oral activity. It is the most common estrogen in combined pills.
Key Pharmaceutical Properties
| Property | Levonorgestrel | Ethinylestradiol |
|---|---|---|
| Lipophilicity (logP) | 3.8 | 3.6 |
| Protein binding | 97‑99% (to SHBG & albumin) | 98% (to albumin) |
| Oral bioavailability | ~100% | ~40% (first‑pass effect) |
| Receptor affinity | High for progesterone receptor; low androgen | High for estrogen receptor α/β |
🗒️ Pharmaceutical insight: The 150 mcg levonorgestrel dose provides strong progestogenic activity while the 30 mcg ethinylestradiol ensures cycle control and enhances contraceptive efficacy by suppressing gonadotropins.
Mechanism of Action: Dual Hormonal Pathway
Ovranette prevents conception through three complementary actions:
- Ovulation inhibition (primary mechanism): Ethinylestradiol and levonorgestrel together suppress hypothalamic GnRH, reducing pituitary secretion of FSH and LH. Without the LH surge, ovulation does not occur.
- Cervical mucus thickening: Levonorgestrel makes cervical mucus thick, sparse, and less penetrable, forming a physical barrier that impedes sperm migration.
- Endometrial alteration: The progestogen induces atrophic changes in the endometrium, making it unfavourable for implantation even if fertilisation were to occur.
| Feature | Levonorgestrel | Ethinylestradiol |
|---|---|---|
| Primary target | Progesterone receptors (cervix, endometrium, pituitary) | Estrogen receptors (hypothalamus, pituitary, liver) |
| Onset of action | Cervical changes within 48 h | FSH suppression within days |
| Peak contraceptive effect | 7 days of consistent use | 7 days of consistent use |
🗒️ Physiological insight: The combination provides a multi‑level safety net: even if ovulation occasionally occurs, the mucus and endometrial changes offer backup protection.
Absorption & Distribution (Pharmacokinetics)
After oral administration, both hormones are rapidly absorbed. Levonorgestrel reaches peak plasma concentration within 1‑2 h, ethinylestradiol within 1‑2 h. Ethinylestradiol undergoes first‑pass metabolism in the gut wall and liver, reducing its absolute bioavailability to about 40%. Levonorgestrel is almost completely bioavailable.
Distribution
Levonorgestrel is highly bound to sex hormone binding globulin (SHBG) and albumin. Ethinylestradiol increases hepatic synthesis of SHBG, which in turn affects levonorgestrel distribution. Volume of distribution: levonorgestrel ~1.4 L/kg, ethinylestradiol ~4 L/kg.
Steady state
After 5‑7 days of daily intake, plasma concentrations reach steady state. Both hormones accumulate slightly due to their half‑lives (levonorgestrel 20‑30 h, ethinylestradiol 10‑20 h).
Metabolic Effects & Elimination Pathways
Levonorgestrel is primarily metabolised by CYP3A4 in the liver to reduced and conjugated metabolites (sulfates and glucuronides), which are inactive. These are excreted in urine (40%) and faeces (60%).
Ethinylestradiol undergoes aromatic hydroxylation (CYP3A4) and conjugation. It also participates in enterohepatic recirculation, which can be interrupted by certain antibiotics or diarrhoea, potentially reducing efficacy. Excretion is similarly renal and faecal.
⚠️ Metabolic caution: Drugs that induce CYP3A4 (e.g., rifampicin, some anticonvulsants, St John’s wort) accelerate metabolism and may reduce contraceptive efficacy. Always check for interactions.
Clinical Efficacy in Contraception & Beyond
When taken correctly (one tablet daily for 21 days, then 7‑day break), Ovranette has a Pearl Index of about 0.3 (i.e., 3 pregnancies per 1000 woman‑years). Typical use (including missed pills) gives a failure rate of approximately 9% in the first year.
Non‑contraceptive benefits demonstrated in clinical use include:
- Reduced menstrual pain (dysmenorrhoea) and premenstrual tension
- Lighter, more regular periods, decreasing risk of iron‑deficiency anaemia
- Long‑term use lowers risk of ovarian and endometrial cancer (up to 50% reduction after 5+ years)
- Improvement in acne for some women (though levonorgestrel has slight androgenic potential)
The pill does not protect against sexually transmitted infections; condom use is advised when at risk.
Ovranette FAQs
How quickly does Ovranette start working?
If you start on the first day of your period, protection is immediate. Starting on any other day requires 7 consecutive pills; use condoms during those 7 days.
What should I do if I miss a pill?
If you are less than 12 hours late, take it immediately and continue as usual. If more than 12 hours, take the last missed pill (even if two are taken in one day) and use extra contraception for 7 days. Check the leaflet for detailed rules.
Can antibiotics stop Ovranette from working?
Most antibiotics (except rifampicin/rifabutin) do not affect hormonal contraception. However, any severe diarrhoea or vomiting can reduce absorption — follow the missed pill advice in those cases.
Does Ovranette cause weight gain?
Weight changes are uncommon with modern low‑dose pills. Some women may experience mild fluid retention, but large studies show no consistent link between combined pills and significant weight gain.
Is Ovranette safe for smokers over 35?
No. Women aged 35+ who smoke 15+ cigarettes daily should not take Ovranette because of a significantly increased risk of cardiovascular and thrombotic events. Discuss non‑hormonal alternatives with your doctor.
Need Ovranette with Expert Guidance?
If you’ve decided that the combined pill is right for you, our UK‑registered doctors can review your medical history and prescribe Ovranette online — with next‑day delivery.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Contraception ConsultationRelated Ovranette Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 17 March 2026
Next Review: 17 September 2026
Published on: 17 March 2026
Last Updated: 17 March 2026